The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity. This study determined the added value of pharmacogenetic testi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerskes, Catharina H. M., van den Eijnde, Carien J. M. E., Aarnoudse, Albert-Jan L. H. J., Grouls, René J. E., Deiman, Birgit A. L. M., Deenen, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145606/
https://www.ncbi.nlm.nih.gov/pubmed/37104075
http://dx.doi.org/10.3390/pharmacy11020069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145606/
https://www.ncbi.nlm.nih.gov/pubmed/37104075
http://dx.doi.org/10.3390/pharmacy11020069

Ejemplares similares